All stocks ยท KILITCH
KD

Kilitch Drugs (I) Ltd.

KILITCH BSE Drug Manufacturers - Specialty & Generic Healthcare

Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoโ€ฆ

ISIN INE729D01010
Listed โ€”
Quarters tracked 13
Filings 20 docs

About

Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, anticoagulant, narcotic, oncology, ophthalmic, antifungal, corticosteroid, anticoagulant, and other applications, as well as vaccines, veterinary products, iron supplements for anemia, Klavmox, and Onecef. It also provides oral formulations, including tablets, capsules, dry syrup, and oral powder for antibiotic, anti-diabetic, cardiovascular, and other areas; effervescent tablets and powders, such as Roipar, Duregra, and Roivit; and nutritional products, including Celtine. In addition, the company offers cosmetics, which include oil, lotion, liquid to cream, paste in skin, and personal and hair care products; herbal products for use in sore throat and prostate problems, as well as a supplement for diabetes, obesity, libido, and other conditions; ortho rehabilitation and implants; and medical devices comprising C-Seal, a skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Further, it provides PH-7, which reduces acid content of the stomach; SRO kit for treating childhood diarrhea; 9-VIT for use in surgery, extensive burns, fractures, and other trauma; and HPURE for sore throat and cough. The company exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.

Key Metrics

as of Sep 2026
Market Cap636 Cr
P/E21.20
Div Yield0.00 %
Book Valueโ‚น80.00
52w Highโ‚น220.00
52w Lowโ‚น117.00
Face Valueโ‚น10.00

Quarterly Results

Rs. Crores ยท hover row for definition
Metric Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023
Sales 44.88 89.60 53.81 48.92 43.14 61.23 56.17 47.47 33.45 44.82 31.79 41.20 36.56
Expenses 41.94 67.46 47.66 43.88 39.88 46.64 47.44 41.37 31.79 37.74 29.51 32.58 30.38
Operating Profit 2.94 22.14 6.15 5.04 3.26 14.59 8.73 6.10 1.66 7.08 2.28 8.62 6.18
OPM % 6.55 24.71 11.43 10.30 7.56 23.83 15.54 12.85 4.96 15.80 7.17 20.92 16.90
Other Income 2.90 0.49 1.53 6.66 2.56 1.70 1.73 5.16 2.57 0.47 2.96 0.49 0.56
Depreciation 1.09 0.98 0.94 0.86 0.84 0.85 0.81 0.61 0.85 0.93 0.81 0.82 0.71
Interest 0.88 1.44 1.15 1.44 1.53 1.60 1.40 0.31 1.73 1.32 1.60 1.51 1.50
Profit before tax 3.87 20.21 5.59 9.40 3.45 13.84 8.25 10.34 1.65 5.30 2.83 6.78 4.53
Tax % 48.84 26.37 22.90 14.47 34.49 26.23 32.00 16.73 93.33 30.57 38.16 24.93 32.67
Net Profit 1.96 14.88 4.31 8.04 2.27 10.22 5.61 8.61 0.11 3.68 1.74 5.09 3.06
EPS in Rs 0.83 4.15 1.27 2.34 0.87 2.97 1.70 2.46 0.38 1.03 0.83 1.35 0.99

Profit & Loss

Annual ยท Rs. Crores
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015
Sales 235.00198.00154.00140.00114.0068.0053.0082.0051.0027.0021.0019.00
Expenses 198.00167.00130.00122.00104.0063.0053.0075.0045.0028.0025.0021.00
Operating Profit 37.0032.0024.0018.0010.005.000.007.006.00-1.00-4.00-2.00
OPM % 16.0016.0016.0013.009.008.000.809.0011.00-2.00-19.00-9.00
Other Income 11.0011.004.003.003.003.004.004.003.001.002.003.00
Interest 6.005.006.005.001.001.001.001.000.000.000.000.00
Depreciation 4.003.003.004.002.002.002.002.002.0010.0010.002.00
Profit before tax 39.0034.0019.0012.0010.005.002.009.006.00-9.00-12.00-1.00
Tax % 24.0028.0030.0031.0035.0027.0048.0055.0016.00-5.00-4.00-70.00
Net Profit 30.0025.0014.008.006.004.001.004.005.00-9.00-11.000.00
EPS in Rs 8.637.634.173.082.171.090.251.151.72-3.09-3.89-0.10
Dividend Payout % 0.000.000.000.000.000.000.0020.0013.000.000.000.00

Balance Sheet

Annual ยท Rs. Crores โ€” latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015
Equity Capital 35.0016.0016.0016.0016.0015.0015.0015.0014.0013.0013.0013.00
Reserves 245.00186.00160.00136.00124.00112.00103.00106.0098.0088.0095.00107.00
Borrowings 89.0049.0032.0022.0020.0015.0013.009.001.001.000.000.00
Other Liabilities 89.0061.0032.0046.0050.0061.0012.0013.0015.0011.008.007.00
Total Liabilities 458.00313.00240.00220.00210.00203.00143.00144.00128.00113.00117.00127.00
Fixed Assets 67.0064.0062.0064.0065.0030.0032.0032.0033.0033.0042.009.00
CWIP 140.0047.006.004.003.0065.0030.0020.003.001.000.000.00
Investments 75.0072.0072.0062.0071.0060.0052.0053.0056.0053.0049.0072.00
Other Assets 176.00129.00100.0090.0071.0047.0030.0038.0035.0026.0025.0046.00
Total Assets 458.00313.00240.00220.00210.00203.00143.00144.00128.00113.00117.00127.00

Cash Flows

Annual ยท Rs. Crores โ€” latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015
Cash from Operating Activity 24.0018.00-2.003.006.0046.004.000.001.001.0017.00-8.00
Cash from Investing Activity -100.00-40.00-8.008.00-15.00-38.00-10.00-14.00-4.00-2.00-20.00-31.00
Cash from Financing Activity 82.0013.009.00-1.007.002.001.0017.006.000.000.000.00
Net Cash Flow 6.00-9.00-1.0010.00-2.0010.00-5.003.002.000.00-2.00-39.00
Free Cash Flow -76.00-29.00-8.00-1.00-2.009.00-6.00-19.00-2.000.00-26.00-10.00
CFO/OP % 92.0082.0023.0039.0079.00877.001,598.0060.0025.00-202.00-442.00430.00

Ratios

Annual ยท Days / % โ€” latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015
Debtor Days 186.00156.00149.00142.00132.00122.00109.0086.00148.00196.00286.00243.00
Inventory Days 33.0053.0018.0010.0028.0035.0070.0036.0039.0084.00110.00124.00
Days Payable 230.00189.00118.00200.00239.00525.0089.0033.00108.00184.00154.00124.00
Cash Conversion Cycle -11.0020.0050.00-48.00-79.00-367.0089.0089.0079.0096.00241.00243.00
Working Capital Days 49.0056.0030.00-4.00-40.00-223.0022.0037.0093.00115.00234.00197.00
ROCE % 13.0016.0013.0010.006.003.001.006.005.00-9.00-10.00โ€”

Shareholding Pattern

% holding โ€” latest first
Holder Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023
Promoters 63.77 63.77 63.77 63.77 69.23 69.23 69.23 69.23 69.23 69.23 69.23 69.23
FIIs 0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Public 36.11 36.22 36.23 36.22 30.77 30.77 30.76 30.77 30.77 30.77 30.76 30.78
No. of Shareholders 12,627 11,785 12,043 10,929 10,379 9,749 10,139 9,920 9,620 9,525 9,062 9,002

Corporate Actions

21 records
ActionEx DateRecord DateRatioAmount (โ‚น)Notes
Bonus 24 Mar 2026 24 Mar 2026 1:1 โ€”
Rights 15 Jul 2025 15 Jul 2025 2:23 โ€”
Other 15 Jul 2025 15 Jul 2025 โ€” โ€” Right Issue of Equity Shares
Other 19 Sep 2024 โ€” โ€” โ€” Annual General Meeting
Other 21 Sep 2023 โ€” โ€” โ€” Annual General Meeting
Other 20 Sep 2022 โ€” โ€” โ€” Annual General Meeting
Other 21 Sep 2021 โ€” โ€” โ€” Annual General Meeting
Other 22 Sep 2020 โ€” โ€” โ€” Annual General Meeting
Dividend 20 Sep 2019 โ€” โ€” 0.50
Dividend 18 Sep 2018 โ€” โ€” 0.50
Other 20 Sep 2017 โ€” โ€” โ€” Annual General Meeting
Other 21 Sep 2016 โ€” โ€” โ€” Annual General Meeting
Other 21 Sep 2015 โ€” โ€” โ€” Annual General Meeting
Other 23 Sep 2014 โ€” โ€” โ€” Annual General Meeting
Other 24 Sep 2013 โ€” โ€” โ€” Annual General Meeting
Dividend 24 Sep 2012 25 Sep 2012 โ€” 30.00
Dividend 18 Aug 2011 โ€” โ€” 1.00
Dividend 14 Oct 2010 15 Oct 2010 โ€” 1.00
Dividend 10 Sep 2009 โ€” โ€” 1.00
Dividend 10 Sep 2008 โ€” โ€” 1.00
Dividend 15 Nov 2007 16 Nov 2007 โ€” 1.00

Announcements

5 filings